Back to Search Start Over

Identity by descent mapping of founder mutations in cancer using high-resolution tumor SNP data

Authors :
Nelly Burnichon
Aliou Sow
Aurélien de Reyniès
Bonald C. Figueiredo
Enzo Lalli
Eric Letouzé
Roberto Rosati
Anne-Paule Gimenez-Roqueplo
Fabien Petel
Cartes d'Identité des Tumeurs (CIT)
Ligue Nationale Contre le Cancer (LNCC)
Instituto de Pesquisa Pelé Pequeno Principe
Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970)
Hôpital Européen Georges Pompidou [APHP] (HEGP)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Service de génétique [CHU HEGP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
Université Paris Descartes - Paris 5 (UPD5)
Institut de pharmacologie moléculaire et cellulaire (IPMC)
Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS)
COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)
Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP)
Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP)
Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
Université Nice Sophia Antipolis (... - 2019) (UNS)
Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS)
Cartes d'Identité des Tumeurs ( CIT )
Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 )
Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Européen Georges Pompidou [APHP] ( HEGP )
Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP )
Université Paris Descartes - Paris 5 ( UPD5 )
Institut de pharmacologie moléculaire et cellulaire ( IPMC )
Université Nice Sophia Antipolis ( UNS )
Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Centre National de la Recherche Scientifique ( CNRS )
Source :
PLoS ONE, PLoS ONE, Public Library of Science, 2012, 7 (5), pp.e35897. ⟨10.1371/journal.pone.0035897⟩, PLoS ONE, Vol 7, Iss 5, p e35897 (2012), PLoS ONE, Public Library of Science, 2012, 7 (5), pp.e35897. 〈10.1371/journal.pone.0035897〉
Publication Year :
2012
Publisher :
HAL CCSD, 2012.

Abstract

International audience; Dense genotype data can be used to detect chromosome fragments inherited from a common ancestor in apparently unrelated individuals. A disease-causing mutation inherited from a common founder may thus be detected by searching for a common haplotype signature in a sample population of patients. We present here FounderTracker, a computational method for the genome-wide detection of founder mutations in cancer using dense tumor SNP profiles. Our method is based on two assumptions. First, the wild-type allele frequently undergoes loss of heterozygosity (LOH) in the tumors of germline mutation carriers. Second, the overlap between the ancestral chromosome fragments inherited from a common founder will define a minimal haplotype conserved in each patient carrying the founder mutation. Our approach thus relies on the detection of haplotypes with significant identity by descent (IBD) sharing within recurrent regions of LOH to highlight genomic loci likely to harbor a founder mutation. We validated this approach by analyzing two real cancer data sets in which we successfully identified founder mutations of well-characterized tumor suppressor genes. We then used simulated data to evaluate the ability of our method to detect IBD tracts as a function of their size and frequency. We show that FounderTracker can detect haplotypes of low prevalence with high power and specificity, significantly outperforming existing methods. FounderTracker is thus a powerful tool for discovering unknown founder mutations that may explain part of the "missing" heritability in cancer. This method is freely available and can be used online at the FounderTracker website.

Details

Language :
English
ISSN :
19326203
Database :
OpenAIRE
Journal :
PLoS ONE, PLoS ONE, Public Library of Science, 2012, 7 (5), pp.e35897. ⟨10.1371/journal.pone.0035897⟩, PLoS ONE, Vol 7, Iss 5, p e35897 (2012), PLoS ONE, Public Library of Science, 2012, 7 (5), pp.e35897. 〈10.1371/journal.pone.0035897〉
Accession number :
edsair.doi.dedup.....39c58f083ea1d5c447480f5d97104c13
Full Text :
https://doi.org/10.1371/journal.pone.0035897⟩